Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon + dendritic cells + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- The Third Affiliated Hospital of Sun Yat-sen University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intradermal, Intramuscular, Intravenous
01
Overview
This combination therapy is an experimental immunotherapeutic regimen developed by the Department of Infectious Diseases at the Third Affiliated Hospital of Sun Yat-sen University for the treatment of advanced hepatocellular carcinoma (HCC). The protocol involves the administration of autologous dendritic cells (DCs) that have been pulsed with HepG2 cell lysate to present a broad spectrum of tumor-associated antigens to the patient's immune system. This is combined with recombinant interferon-alpha (IFN-α), which promotes DC maturation and enhances the cytotoxic activity of T cells and natural killer cells. Additionally, low-dose (metronomic) cyclophosphamide is administered to selectively deplete CD4+CD25+ regulatory T cells (Tregs), thereby reducing immune suppression within the tumor microenvironment and potentiating the vaccine-induced anti-tumor response.
- Other names
- IFN-alpha + DC vaccine + CTXIFN + DC + CTX
Beyond the preview
Go deeper on interferon + dendritic cells + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon + dendritic cells + cyclophosphamide.